Brief: Medivir Reports Results Of Phase IA Study Of MIV-818
18/11/2019 08:06
Nov 18 (Reuters) - Medivir AB MVIRb.ST :
* INITIAL DATA OBSERVED IN PHASE I STUDY SUPPORT OUR VIEW
THAT
MIV-818 HAS POTENTIAL TO PROVIDE A CLEAR AND MUCH NEEDED
IMPROVEMENT IN TREATMENT FOR PATIENTS WITH LIVER CANCER
Source text for Eikon: ID:nWkr28HgQ0
Further company coverage: MVIRb.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))